More News! Berlin’s Biggest Biotech Makes a Deal with Japanese Pharma

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

  • Poxel has signed a deal with Sumitomo Dainippon Pharma to jointly develop its Type 2 Diabetes product Imeglimin
  • Berlin’s largest biotech Glycotope has hammered out a deal with Daiichi Sankyo for its antibody-drug conjugates

  • Sanofi has jettisoned a Phase II program for a lung-scarring disease but gave no reason
  • GSK scored a Breakthrough Designation from the FDA for its multiple myeloma antibody
  • OncoDNA has launched genetic tests in Latin America

Images via kungverylucky, Kobby Dagan, Parkol /



Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.